Anti-factor Xa assay in patients with atrial fibrillation

Anti-factor Xa assay in patients with atrial fibrillation - Anti-factor Xa assay in patients with atrial fibrillation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046323

Enrollment

210

Registered

2021-12-08

Start date

2021-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Twice blood examination, edoxaban. Twice blood examination, apixaban. Twice blood examination, Rivaroxaban.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AF patients who have taken factor Xa inhibitors.

Exclusion criteria

Exclusion criteria: AF patients who have side effect of factor Xa inhibitors.

Design outcomes

Primary

Measure	Time frame
anti-factor Xa activity	—

Secondary

Measure	Time frame
Cardiovascular events after 1 year	—

Countries

Japan

Contacts

Public ContactTakanori Arimoto

Yamagata University School of Medicine Department of cardiology

t-arimoto@med.id.yamagata-u.ac.jp023-628-5302

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026